GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA
Kristina K. Kachiyeva Z. Abetova A. Raspopova N.
October 2024Georgian Association of Business Press
Georgian Medical News
2024#355Issue 1099 - 116 pp.
Schizophrenia is a multifaceted psychiatric disorder characterized by hallucinations, delusions, cognitive impairments, and behavioral disturbances. Genetic factors significantly contribute to its pathogenesis, accounting for approximately 80% of the heritability. Globally, about 1% of the population is affected by schizophrenia, with 45,054 individuals in Kazakhstan receiving medical treatment for the condition, indicating a prevalence rate of 238,6 per 100,000 people. The rise in mental health disorders in Kazakhstan underscores the need for personalized treatment approaches to address these public health challenges. This study examines the influence of key polymorphisms—CYP2D6 (rs1135840), CYP3A5 (rs776746), COMT (rs4818, rs4680, rs9606186), CNR1 (rs1049353), HTR2A (rs6311, rs6313), and DRD2 (rs1799978, rs1800497)—on AP drug metabolism and therapeutic outcomes. The findings underscore the potential for genotype-guided AP dosage individualization in Kazakh individuals, laying a foundation for future research on optimizing AP therapy in this population.
antipsychotics , central Asian , CNR1 , COMT , CYP2D6 , DRD2 , HTR2A , Kazakh ethnic group , Paranoid schizophrenia , pharmacogenetics , SNPs
Text of the article Перейти на текст статьи
S.D. Asfendiyarov Kazakh National Medical University, Tole bi st., 94, Almaty, 050000, Kazakhstan
Republican Scientific and Practical Center of Mental Health, Almaty, Kazakhstan
Kazakh Russian Medical University, Almaty, Kazakhstan
S.D. Asfendiyarov Kazakh National Medical University
Republican Scientific and Practical Center of Mental Health
Kazakh Russian Medical University
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026